Tezepelumab, a humanized monoclonal antibody targeting the upstream asthma inflammatory mediator Thymic Stromal Lymphopoietin (TSLP), is a potential treatment option for severe non-T2 asthma patients [15]. Here, TSLP is linked to asthma.